Funding Childhood Cancer
Funding research and clinical trials for children, adolescents and young adults with cancer is about looking forward, pushing on the science, and doing better for children who are diagnosed with cancer in the future. Kindred Foundation is proud to partner with organizations from around the world to fund research that will make a difference in the lives of kids with cancer.
2023 Kindred Foundation Funding for Childhood Cancer Initiatives
Defeating Embryonal Cancer in Young People Together (DECRYPT)
2022 Kindred Foundation Funding for Childhood Cancer Initiatives
The ACTION Consortium: Funding Neuroblastoma Cancer Research
We are excited to announce the first Research Funding Award by the ACTION Consortium. Founded by five non-profit organizations: The Anticancer Fund, The Evan Foundation, Kindred Foundation, Solving Kids’ Cancer UK and Zoé4Life. The ACTION Consortium is a collective force committed to Advancing Clinical Trial Implementation and Optimisation in Neuroblastoma (ACTION).
Childhood Blood Cancer Research Innovation Grant
Identifying the Genetic Changes that Lead to Ruxolitinib Resistance
Modern chemotherapy regimens can cure acute lymphoblastic leukemia (ALL) in most children, adolescents, and young adults. Unfortunately, outcomes remain poor for children whose ALL is caused by certain high-risk genetic mutations, known as Ph-like ALL. This subtype occurs very commonly in children and is more frequent in individuals of Hispanic/Latino and Indigenous ancestry. Ph-like ALL often comes back even with the best available chemotherapy.
A new targeted therapy called ruxolitinib was created to block an important pathway that contributes to the cancerous behaviour of Ph-like ALL cells. A phase 2 clinical trial is ongoing to test whether adding ruxolitinib to chemotherapy can decrease relapses in children with Ph-like ALL. However, some children have already relapsed, suggesting that their leukemia cells found a way to outsmart the drugs and become resistant.
In this project, the researchers are studying blood and bone marrow samples from pediatric Ph-like ALL participants in the clinical trial. They hope to learn why leukemia cells can sometimes outsmart the drugs and lead to relapse, either by developing DNA mutations or rewiring the pathways inside the cells to hide from the drugs. The results will be used to identify new therapies that attack other leukemia cell targets with a goal of overcoming or even preventing resistance to ruxolitinib in patients with Ph-like ALL.
MiR-193a-Based LNP Drug Treatment for Pediatric Acute Myeloid Leukemia
COVID-19 and mRNA-based therapeutics used to treat it have changed the world. Key to their success was the
Dr. Kuchenbauer’s research group and others have recently highlighted the potential of microRNA (miRNA) encapsulated LNPs to target specific mutations in leukemias, with fewer side effects. The team’s previous data showed that miR-193a (a gene associated with cancer) is significantly decreased in pediatric normal karyotype AML (CN-AML) . In CN-AML, it has been shown that engineered over-expression of miR-193a slowed down the
You can read more on The Leukemia and Lymphoma Society of Canada website.
Fit ABCS Clinical Trial for Childhood Brain Cancer Survivors
2021 Kindred Foundation Funding for Childhood Cancer Initiatives
Funding the Oncology Resource Navigator Role at SickKids
A childhood cancer diagnosis is devastating. You immediately enter a new world with a myriad of appointments, clinic visits, and forms, coupled with the financial, emotional, and social burdens that permeate the entire family’s lives. But when focusing on your child, it’s hard to find time or energy to seek out the resources that can help. Three years ago, to make the treacherous cancer journey for families a little easier, the Garron Family Cancer Centre (GFCC) at SickKids began a Resource Navigation pilot project as part of the Centre’s burgeoning Psychosocial Program. It quickly became an essential support network for families and patients, but funding for the project was scarce. Kindred Foundation is proud to be a new supporter of the SickKids oncology Resource Navigator program.
Lead Funder of the Childhood Cancer Canada Benevolent Fund
In 2021, Kindred Foundation became the lead funder of the Benevolent Fund operated by Childhood Cancer Canada. The Benevolent Fund assists families with the cost of their child's funeral when they die from cancer.
There are too many losses and costs that come with childhood cancer. Unfortunately, if a child dies from cancer, a family may not have the means to be able to provide for an appropriate burial for their child. Every family should be able to bury their child with grace and dignity.
In 2022, Childhood Cancer Canada will increase the amount of financial assistance from up to $1,000 to $1,500 to better support families in a time when they need it most. To access the fund, the family's Social Workers provides the necessary information, and if approved, Childhood Cancer Canada makes a payment directly to the funeral service provider. Kindred Foundation is very proud to be able to support the Benevolent Fund and also make it possible to increase the amount of funding that is available for bereaved childhood cancer families.
The Benevolent Fund is the only national program of its kind, providing support to families across Canada. We are pleased that 100% of the donation provided will be allocated to the Benevolent Fund. Please see the Childhood Cancer Canada website for more information about the Benevolent Fund.
Funding Research for Adolescents and Young Adults with Cancerous Brain Tumours
Kindred Foundation partnered to fund a Canadian adolescent and young adult (AYA) grant focused on the "Molecular Classification of Primary CNS Tumours in Adolescent and Young Adults." The proposal from Dr. Uri Tabori, Dr. Julie Bennett and Dr. Cynthia Hawkins was selected by the C17 Research Network and co-funded by Kindred Foundation with the Canadian Cancer Clinical Trials Network and the Michael Kamin Hart Research Fund.